Two approaches to comparing hospital charges between cadaveric renal transplant patients who received orthoclone OKT3 sterile solution or Atgam sterile solution for induction therapy.
The objectives of this study were :
(1) to compare total hospital charges for a sample of cadaveric renal transplant patients categorized according to the type of induction therapy used (Orthoclone OKT3 Sterile Solution or Atgam Sterile Solution) ; (2) to compare specific charge categories between the two groups ; and (3) to examine the relationship between charges and a set of independent variables.
A retrospective review was conducted of hospital charges associated with a sample of renal transplant patients.
The overall sample for this study comprised 510 patient discharges from 22 hospitals in the United States.
Comparisons between the OKT3 and Atgam groups were made for total and specific charge categories using two different approaches to help control variations in charges that were not related to the type of induction therapy used.
The results showed that higher drug charges in the Atgam group were offset by lower charges in other categories (P<0.05).
These findings suggest that hospital formulary committees should consider all relevant costs, not just drug acquisition costs, when selecting products.
However, further investigation is warranted to explore differences in charges due to :
(1) between-hospital variation ;
(2) patients'severity of illness before receiving induction therapy ;
and (3) differences in side-effect profiles for the two induction therapies.
Mots-clés Pascal : Homotransplantation, Rein, Coût financement, Transplantation, Rejet, Economie santé, Etude comparative, Homme, Traitement induction, Immunodépresseur, Immunothérapie, Prévention, Hôpital, Milieu hospitalier, Rapport coût bénéfice, Anticorps OKT3, Atgam, Rein pathologie, Appareil urinaire pathologie
Mots-clés Pascal anglais : Homotransplantation, Kidney, Financing cost, Transplantation, Rejection, Health economy, Comparative study, Human, Induction treatment, Immunosuppressive agent, Immunotherapy, Prevention, Hospital, Hospital environment, Cost benefit ratio, Renal disease, Urinary system disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0576013
Code Inist : 002B30A04B. Création : 01/03/1996.